Repurposing anthelmintic agents to eradicate resistant leukemia.
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
26 06 2020
26 06 2020
Historique:
received:
05
05
2020
accepted:
08
06
2020
revised:
04
06
2020
entrez:
28
6
2020
pubmed:
28
6
2020
medline:
11
5
2021
Statut:
epublish
Résumé
Despite rapid progress in genomic profiling in acute lymphoblastic leukemia (ALL), identification of actionable targets and prediction of response to drugs remains challenging. To identify specific vulnerabilities in ALL, we performed a drug screen using primary human ALL samples cultured in a model of the bone marrow microenvironment combined with high content image analysis. Among the 2487 FDA-approved compounds tested, anthelmintic agents of the class of macrocyclic lactones exhibited potent anti-leukemia activity, similar to the already known anti-leukemia agents currently used in induction chemotherapy. Ex vivo validation in 55 primary ALL samples of both precursor B cell and T-ALL including refractory relapse cases confirmed strong anti-leukemia activity with IC
Identifiants
pubmed: 32591499
doi: 10.1038/s41408-020-0339-9
pii: 10.1038/s41408-020-0339-9
pmc: PMC7320149
doi:
Substances chimiques
Anthelmintics
0
Antineoplastic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
72Références
Pui, C. H. et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J. Clin. Oncol. 33, 2938–2948 (2015).
pubmed: 26304874
pmcid: 4567699
Schrappe, M. et al. Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000. Klin. Padiatr. 225(Suppl 1), S62–S72 (2013).
pubmed: 23700060
Bhojwani, D. & Pui, C. H. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol. 14, e205–e217 (2013).
pubmed: 23639321
Chen, K. H. et al. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. Leukemia 31, 2151–2160 (2017).
pubmed: 28074066
pmcid: 5629371
Pan, J. et al. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Leukemia 31, 2587–2593 (2017).
pubmed: 28490811
von Stackelberg, A. et al. Phase I/Phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J. Clin. Oncol. 34, 4381–4389 (2016).
Fischer, U. et al. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat. Genet. 47, 1020–1029 (2015).
pubmed: 26214592
pmcid: 4603357
Peirs, S. et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood 124, 3738–3747 (2014).
pubmed: 25301704
Jerchel, I. S. et al. RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia. Leukemia 32, 931–940 (2018).
pubmed: 28972594
Liu, Q. et al. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Res. 73, 2574–2586 (2013).
pubmed: 23436801
pmcid: 3760004
McComb, S. et al. Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL. Sci. Transl. Med. 8, 339ra70 (2016).
pubmed: 27194728
Brumatti, G. et al. The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia. Sci. Transl. Med. 8, 339ra69 (2016).
pubmed: 27194727
Pantziarka, P. Scientific advice—is drug repurposing missing a trick? Nat. Rev. Clin. Oncol. 14, 455–456 (2017).
pubmed: 28534529
Pushpakom, S. et al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41–58 (2019).
pubmed: 30310233
Frismantas, V. et al. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood 129, e26–e37 (2017).
pubmed: 28122742
pmcid: 5356455
Conter, V. et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 115, 3206–3214 (2010).
pubmed: 20154213
Schmitz, M. et al. Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. Blood 118, 1854–1864 (2011).
pubmed: 21670474
Malo, N. et al. Statistical practice in high-throughput screening data analysis. Nat. Biotechnol. 24, 167–175 (2006).
pubmed: 16465162
Boutros, M., Bras, L. P. & Huber, W. Analysis of cell-based RNAi screens. Genome Biol. 7, R66 (2006).
pubmed: 16869968
pmcid: 1779553
Prummer, M. Hypothesis testing in high-throughput screening for drug discovery. J. Biomol. Screen 17, 519–529 (2012).
pubmed: 22233646
Ianevski, A. et al. SynergyFinder: a web application for analyzing drug combination dose-response matrix data. Bioinformatics 33, 2413–2415 (2017).
pubmed: 28379339
pmcid: 5554616
Yadav, B. et al. Searching for drug synergy in complex dose-response landscapes using an interaction potency model. Comput. Struct. Biotechnol. J. 13, 504–513 (2015).
pubmed: 26949479
pmcid: 4759128
McComb, S. et al. Efficient apoptosis requires feedback amplification of upstream apoptotic signals by effector caspase-3 or -7. Sci. Adv. 5, eaau9433 (2019).
pubmed: 31392262
pmcid: 6669006
Huang, Y. et al. The leukemogenic TCF3-HLF complex rewires enhancers driving cellular identity and self-renewal conferring EP300 vulnerability. Cancer Cell 36, 630–644 e9 (2019).
pubmed: 31735627
Fava, L. L. et al. The PIDDosome activates p53 in response to supernumerary centrosomes. Genes Dev. 31, 34–45 (2017).
pubmed: 28130345
pmcid: 5287111
Melotti, A. et al. The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer. EMBO Mol. Med. 6, 1263–1278 (2014).
pubmed: 25143352
pmcid: 4287931
Wang, K. et al. Ivermectin induces PAK1-mediated cytostatic autophagy in breast cancer. Autophagy 12, 2498–2499 (2016).
pubmed: 27657889
pmcid: 5173258
Dou, Q. et al. Ivermectin induces cytostatic sutophagy by nlocking the PAK1/Akt axis in breast vancer. Cancer Res. 76, 4457–4469 (2016).
pubmed: 27302166
Fritz, L. C., Wang, C. C. & Gorio, A. Avermectin B1a irreversibly blocks postsynaptic potentials at the lobster neuromuscular junction by reducing muscle membrane resistance. Proc. Natl Acad. Sci. USA 76, 2062–2066 (1979).
pubmed: 287043
Cully, D. F. et al. Cloning of an avermectin-sensitive glutamate-gated chloride channel from Caenorhabditis elegans. Nature 371, 707–711 (1994).
pubmed: 7935817
Prichard, R., Menez, C. & Lespine, A. Moxidectin and the avermectins: consanguinity but not identity. Int. J. Parasitol. Drugs Drug Resist. 2, 134–153 (2012).
pubmed: 24533275
pmcid: 3862425
Krusek, J. & Zemkova, H. Effect of ivermectin on gamma-aminobutyric acid-induced chloride currents in mouse hippocampal embryonic neurones. Eur. J. Pharmacol. 259, 121–128 (1994).
pubmed: 7957605
Shan, Q., Haddrill, J. L. & Lynch, J. W. Ivermectin, an unconventional agonist of the glycine receptor chloride channel. J. Biol. Chem. 276, 12556–12564 (2001).
pubmed: 11278873
Krause, R. M. et al. Ivermectin: a positive allosteric effector of the alpha7 neuronal nicotinic acetylcholine receptor. Mol. Pharmacol. 53, 283–294 (1998).
pubmed: 9463487
Khakh, B. S. et al. Allosteric control of gating and kinetics at P2X(4) receptor channels. J. Neurosci. 19, 7289–7299 (1999).
pubmed: 10460235
pmcid: 6782529
Ko, S. K. et al. Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells. Nat. Chem. 6, 885–892 (2014).
pubmed: 25242483
Galluzzi, L. et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 25, 486–541 (2018).
pubmed: 29362479
pmcid: 5864239
Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421–3428 (2008).
pubmed: 18451170
Pui, C. H. & Evans, W. E. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354, 166–178 (2006).
pubmed: 16407512
Sharmeen, S. et al. The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells. Blood 116, 3593–3603 (2010).
pubmed: 20644115
Song, D. et al. Moxidectin inhibits glioma cell viability by inducing G0/G1 cell cycle arrest and apoptosis. Oncol. Rep. 40, 1348–1358 (2018).
pubmed: 30015956
pmcid: 6072399
Kinrade, S. A. et al. Evaluation of the cardiac safety of long-acting endectocide moxidectin in a randomized concentration-QT study. Clin. Transl. Sci. 11, 582–589 (2018).
pubmed: 30117300
pmcid: 6226119
Laing, R., Gillan, V. & Devaney, E. Ivermectin—old drug, new tricks? Trends Parasitol. 33, 463–472 (2017).
pubmed: 28285851
pmcid: 5446326
Opoku, N. O. et al. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial. Lancet 392, 1207–1216 (2018).
pubmed: 29361335
pmcid: 6172290
Paul, A. J., Tranquilli, W. J. & Hutchens, D. E. Safety of moxidectin in avermectin-sensitive collies. Am. J. Vet. Res. 61, 482–483 (2000).
pubmed: 10803640
Cotreau, M. M. et al. The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans. J. Clin. Pharmacol. 43, 1108–1115 (2003).
pubmed: 14517193
Prichard, R. K. & Geary, T. G. Perspectives on the utility of moxidectin for the control of parasitic nematodes in the face of developing anthelmintic resistance. Int. J. Parasitol. Drugs Drug Resist. 10, 69–83 (2019).
pubmed: 31229910
pmcid: 6593148
Ghosh, T. et al. Closing the brief case: crusted scabies in a leukemic patient following a stay in a long-term acute care facility. J. Clin. Microbiol. 55, 1599–1600 (2017).
pubmed: 28442617
pmcid: 5405284
Yonekura, K. et al. Crusted scabies in an adult T-cell leukemia/lymphoma patient successfully treated with oral ivermectin. J. Dermatol. 33, 139–141 (2006).
pubmed: 16556285
Molinari, G., Soloneski, S. & Larramendy, M. L. New ventures in the genotoxic and cytotoxic effects of macrocyclic lactones, abamectin and ivermectin. Cytogenet. Genome Res. 128, 37–45 (2010).
pubmed: 20389039
Zhang, X. et al. Inhibition of TMEM16A Ca(2+)-activated Cl(-) channels by avermectins is essential for their anticancer effects. Pharmacol. Res. 156, 104763 (2020).
pubmed: 32201246
Crottes, D. & Jan, L. Y. The multifaceted role of TMEM16A in cancer. Cell Calcium 82, 102050 (2019).
pubmed: 31279157
Park, S. H. et al. Determinants of ion-transporter cancer cell death. Chem 5, 2079–2098 (2019).
Britschgi, A. et al. Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling. Proc. Natl Acad. Sci. USA 110, E1026–E1034 (2013).
pubmed: 23431153
Song, Y. et al. Inhibition of ANO1/TMEM16A induces apoptosis in human prostate carcinoma cells by activating TNF-alpha signaling. Cell Death Dis. 9, 703 (2018).
pubmed: 29899325
pmcid: 5999606
Gururaja Rao, S., Patel, N. J. & Singh, H. Intracellular chloride channels: novel biomarkers in diseases. Front. Physiol. 11, 96 (2020).
pubmed: 32116799
pmcid: 7034325
Jing, D. et al. Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells. Blood 125, 273–283 (2015).
pubmed: 25336632